MetaCap

Merck (MRK) vs Novartis (NVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Merck (MRK) has outperformed Novartis (NVS) over the past year, gaining 36.8% versus a gain of 18.2%. Over five years, NVS leads with a +86.5% price change compared with +68.9% for MRK. Merck is the larger company by market cap ($329.65 billion vs $284.18 billion), about 1.2 times the size.

On valuation, Merck trades at a lower forward P/E (14.9x vs 15.1x for Novartis). Novartis offers the higher dividend yield (3.10% vs 2.51%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRK+36.78%NVS+18.19%
+63%+30%-4%
Nov 21, 20251 yearNov 20, 2026
MRK+65.70%NVS+84.26%
+112%+48%-16%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRK versus NVS key metrics
MetricMRKNVS
Share price$133.72$150.47
Market cap$329.65B$284.18B
1-day change+0.69%-0.50%
YTD return+27.04%+9.14%
1-year return+36.78%+18.19%
5-year return+68.92%+86.46%
P/E ratio (TTM)135.0728.72
Forward P/E14.9215.15
EPS (TTM)$0.99$5.24
Dividend yield2.51%3.10%
Annual dividend$3.36$4.67
Revenue (latest FY)$65.01B—
Revenue growth (YoY)+1.31%—
Net income (latest FY)$18.25B$13.98B
Gross margin74.80%—
Net margin28.08%—
52-week high$156.92$170.46
52-week low$96.06$126.50
Distance from 52-week high-14.78%-11.73%
Analyst consensusbuyhold
Avg. price target upside+20.80%+4.41%
Average volume9.81M2.18M
Shares outstanding2.47B1.89B
Employees73,00075,267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRK has outperformed NVS by 18.6 percentage points over the past year.
  • Merck trades at a higher earnings multiple (135.1x vs 28.7x trailing P/E).

About Merck

MRK stock →

Merck & Co., Inc. operates as a healthcare company worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

MRK vs NVS FAQ

Which is bigger, Merck or Novartis?

Merck (MRK) is larger, with a market capitalization of $329.65B compared with $284.18B for Novartis (NVS).

Which stock has performed better over the past year, MRK or NVS?

MRK returned +36.78% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, MRK or NVS?

NVS has the lower trailing P/E at 28.7, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Merck or Novartis?

Novartis has the higher yield at 3.10%, compared with 2.51% for Merck.

Are Merck and Novartis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons